# Exenatide for type 2 diabetes.

> PubMed lists PMID 19135608 in Lancet (London, England) as Letter, Comment, with publication-date metadata of 2009-01-10 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19135608-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19135608-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-19135608-exenatide-v1.json
- Content SHA-256: `0a018524da918fe036c27d9ab876b7630c9e327415247cbb1c655b42cecf779d`

## Claims and source pins

### Headline

Exenatide for type 2 diabetes. ([`pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb`](#source-pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb))

### Summary

PubMed lists PMID 19135608 in Lancet (London, England) as Letter, Comment, with publication-date metadata of 2009-01-10 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb`](#source-pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb))

### Paragraph 1

PubMed lists PMID 19135608 in Lancet (London, England) as Letter, Comment, with publication-date metadata of 2009-01-10 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb`](#source-pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb`](#source-pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb))

## Sources

<a id="source-pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb"></a>
- **Exenatide for type 2 diabetes. · retained source version 1:2026-01-28:current:b7ff3c5ddfdb7fccbcc4b7a8b8a04a5d019e7e020d953b3b76b81689fb7d98f2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19135608/) (`pubmed-observation-pmid-19135608-2026-01-28-b7ff3c5ddfdb`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Exenatide for type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-19135608-exenatide-v1.json SHA-256: 0a018524da918fe036c27d9ab876b7630c9e327415247cbb1c655b42cecf779d.